|
1
|
Zajac AJ, Blattman JN, Murali-Krishna K,
Sourdive DJ, Suresh M, Altman JD and Ahmed R: Viral immune evasion
due to persistence of activated T cells without effector function.
J Exp Med. 188:2205–2213. 1998.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Gallimore A, Glithero A, Godkin A, Tissot
AC, Plückthun A, Elliott T, Hengartner H and Zinkernagel R:
Induction and exhaustion of lymphocytic choriomeningitis
virus-specific cytotoxic T lymphocytes visualized using soluble
tetrameric major histocompatibility complex class I-peptide
complexes. J Exp Med. 187:1383–1393. 1998.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Fuller MJ, Khanolkar A, Tebo AE and Zajac
AJ: Maintenance, loss, and resurgence of T cell responses during
acute, protracted, and chronic viral infections. J Immunol.
172:4204–4214. 2004.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Wherry EJ: T cell exhausion. Nat Immunol.
12:492–499. 2011.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Doering TA, Crawford A, Angelosanto JM,
Paley MA, Ziegler CG and Wherry EJ: Network and analysis reveals
centrally connected genes and pathways involved in CD8+ T cell
exhaustion versus memory. Immunity. 37:1130–1144. 2012.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Schietinger A and Greenberg PD: Tolerance
and exhaustion: Defining mechanisms of T cell dysfunction. Trends
Immunol. 35:51–60. 2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Butte MJ, Keir ME, Phamduy TB, Sharpe AH
and Freeman GJ: Programmed death-1ligand 1 interacts specifically
with the B7-1 costimulatory molecule to inhibit T cell responses.
Immunity. 27:111–122. 2007.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Freeman GJ, Long AJ, Iwai Y, Bourque K,
Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne
MC, et al: Engagement of the PD-1 immunoinhibitory receptor by a
novel B7 family member leads to negative regulation of lymphocyte
activation. J Exp Med. 192:1027–1034. 2000.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Couzin-Frankel J: Breakthrough of the year
2013. Cancer immunotherapy. Science. 342:1432–1433. 2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Butt AQ and Mills KH: Immunosuppressive
networks and checkpoints controlling antitumor immunity and their
blockade in the development of cancer immunotherapeutics and
vaccines. Oncogene. 33:4623–4631. 2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Merelli B, Massi D, Cattaneo L and Mandalà
M: Targeting the PD1/PD-L1 axis in melanoma: Biological rationale,
clinical challenges and opportunities. Crit Rev Oncol Hematol.
89:140–165. 2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Garon EB, Rizvi NA, Hui R, Leighl N,
Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L,
et al: Pembrolizumab for the treatment of non-small-cell lung
cancer. N Engl J Med. 372:2018–2028. 2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Rosenberg JE, Hoffman-Censits J, Powles T,
van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH,
Balmanoukian A, Loriot Y, et al: Atezolizumab in patients with
locally advanced and metastatic urothelial carcinoma who have
progressed following treatment with platinum-based chemotherapy: A
single-arm, multicentre, phase 2 trial. Lancet. 387:1909–1920.
2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Ansell SM, Lesokhin AM, Borrello I,
Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry
D, Freeman GJ, et al: PD-1 blockade with nivolumab in relapsed or
refractory Hodgkin's lymphoma. N Engl J Med. 372:311–319. 2015.
View Article : Google Scholar
|
|
15
|
Motzer RJ, Escudier B, McDermott DF,
George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G,
Plimack ER, et al: Nivolumab versus everolimus in advanced
renal-cell carcinoma. N Engl J Med. 373:1803–1813. 2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Caspi RR: Immunotherapy of autoimmunity
and cancer: The penalty for success. Nat Rev Immunol. 8:970–976.
2008.PubMed/NCBI View
Article : Google Scholar
|
|
17
|
Amos SM, Duong CP, Westwood JA, Ritchie
DS, Junghans RP, Darcy PK and Kershaw MH: Autoimmunity associated
with immunotherapy of cancer. Blood. 118:499–509. 2011.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Lin DY, Tanaka Y, Iwasaki M, Gittis AG, Su
HP, Mikami B, Okazaki T, Honjo T, Minato N and Garboczi DN: The
PD-1/PD-L1 complex resembles the antigen-binding Fv domains of
antibodies and T cell receptors. Pro Natl Acad Sci USA.
105:3011–3016. 2008.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Dong H, Zhu G, Tamada K and Chen L: B7-H1,
a third member of the B7 family, co-stimulates T-cell proliferation
and interleukin-10 secretion. Nat Med. 5:1365–1369. 1999.PubMed/NCBI View
Article : Google Scholar
|
|
20
|
Freeman GJ, Long AJ, Iwai Y, Bourque K,
Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne
MC, et al: Engagement of the PD-1 immunoinhibitory receptor by a
novel B7 family member leads to negative regulation of lymphocyte
activation. J Exp Med. 192:1027–1034. 2000.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Dong H, Strome SE, Salomao DR, Tamura H,
Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al:
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential
mechanism of immune evasion. Nat Med. 8:793–800. 2002.PubMed/NCBI View
Article : Google Scholar
|
|
22
|
Ding H, Wu X and Gao W: PD-L1 is expressed
by human renal tubular epithelial cells and suppresses T cell
cytokine synthesis. Clin Immunol. 115:184–191. 2005.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Yang CY, Lin MW, Chang YL, Wu CT and Yang
PC: Programmed cell death-ligand 1 expression in surgically
resected stage I pulmonary adenocarcinoma and its correlation with
driver mutations and clinical outcomes. Eur J Cancer. 50:1361–1369.
2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M,
Nakajima Y, Zhou J, Li BZ, Shi YH, Xiao YS, et al: Overexpression
of PD-L1 significantly associates with tumor aggressiveness and
postoperative recurrence in human hepatocellular carcinoma. Clin
Cancer Res. 15:971–979. 2009.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Hino R, Kabashima K, Kato Y, Yagi H,
Nakamura M, Honjo T, Okazaki T and Tokura Y: Tumor cell expression
of programmed cell death-1 ligand 1 is a prognostic factor for
malignant melanoma. Cancer. 116:1757–1766. 2010.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Kikuchi H, Saito Y, Sekiya J, Okano Y,
Saito M, Nakahata N, Kubohara Y and Oshima Y: Isolation and
synthesis of a new aromatic compound, brefelamide, from
dictyostelium cellular slime molds and its inhibitory effect on the
proliferation of astrocytoma cells. J Org Chem. 70:8854–8858.
2005.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Honma S, Saito M, Kikuchi H, Saito Y,
OshimaY Nakahata N and Yoshida M: A reduction of epidermal growth
factor receptor is involved in brefelamide induced inhibition of
phosphorylation of ERK in human astrocytoma cells. Eur J Pharmacol.
616:38–42. 2009.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Zhang J, Yamada O, Kida S, Matsushita Y,
Murase S, Hattori T, Kubohara Y, Kikuchi H and Oshima Y:
Identification of brefelamide as a novel inhibitor of osteopontin
that suppresses invasion of A549 lung cancer cells. Oncol Rep.
36:2357–2364. 2016.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Janse van Rensburg HJ, Azad T, Ling M, Hao
Y, Snetsinger B, Khanal P, Minassian LM, Graham CH, Rauh MJ and
Yang X: The hippo pathway component TAZ promotes immune evasion in
human cancer through PD-L1. Cancer Res. 78:1457–1470.
2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Yamamoto R, Nishikori M, Tashima M, Sakai
T, Ichinohe T, Takaori-Kondo A, Ohmori K and Uchiyama T: B7-H1
expression is regulated by MEK/ERK signaling pathway in anaplastic
large cell lymphoma and Hodgkin lymphoma. Cancer Sci.
100:2093–2100. 2009.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Jiang X, Zhou J, Giobbie-Hurder A, Wargo J
and Hodi FS: The activation of MAPK in melanoma cells resistant to
BRAF inhibition promotes PD-L1 expression that is reversible by MEK
and PI3K inhibition. Clin Cancer Res. 19:598–609. 2013.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Atefi M, Avramis E, Lassen A, Wong DJ,
Robert L, Foulad D, Cerniglia M, Titz B, Chodon T, Graeber TG, et
al: Effects of MAPK and PI3K pathways on PD-L1 expression in
melanoma. Clin Cancer Res. 20:3446–3457. 2014.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Mestas J and Hughes CC: Of mice and not
men: Differences between mouse and human immunology. J Immunol.
172:2731–2738. 2004.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Davis MM: A prescription for human
immunology. Immunity. 29:835–838. 2008.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Hayday AC and Peakman M: The habitual,
diverse and surmountable obstacles to human immunology research.
Nat Immunol. 9:575–580. 2008.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Naidoo J, Page DB, Li BT, Connell LC,
Schindler K, Lacouture ME, Postow MA and Wolchok JD: Toxicities of
the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann
Oncol. 26:2375–2391. 2015.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Champiat S, Lambotte O, Barreau E, Belkhir
R, Berdelou A, Carbonnel F, Cauquil C, Chanson P, Collins M,
Durrbach A, et al: Management of immune checkpoint blockade
dysimmune toxicities: A collaborative position paper. Ann Oncol.
27:559–574. 2016.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Shay T, Jojic V, Zuk O, Rothamel K,
Puyraimond-Zemmour D, Feng T, Wakamatsu E, Benoist C, Koller D and
Regev A: ImmGen Consortium: Conservation and divergence in the
transcriptional programs of the human and mouse immune systems.
Proc Natl Acad Sci USA. 110:2946–2951. 2013.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Diehl AG and Boyle AP: Conserved and
species-specific transcription factor co-binding patterns drive
divergent gene regulation in human and mouse. Nucleic Acids Res.
46:1878–1894. 2018.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Vierstra J, Rynes E, Sandstrom R, Zhang M,
Canfield T, Hansen RS, Stehling-Sun S, Sabo PJ, Byron R, Humbert R,
et al: Mouse regulatory DNA landscapes reveal global principles of
cis-regulatory evolution. Science. 346:1007–1012. 2014.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Odom DT, Dowell RD, Jacobsen ES, Gordon W,
Danford TW, MacIsaac KD, Rolfe PA, Conboy CM, Gifford DK and
Fraenkel E: Tissue-specific transcriptional regulation has diverged
significantly between human and mouse. Nat Genet. 39:730–732.
2007.PubMed/NCBI View
Article : Google Scholar
|
|
42
|
Harvey KF, Zhang X and Thomas DM: The
Hippo pathway and human cancer. Nat Rev Cancer. 13:246–257.
2013.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Chen Q, Zhang N, Gray RS, Li H, Ewald AJ,
Zahnow CA and Pan D: A temporal requirement for Hippo signaling in
mammary gland differentiation, growth, and tumorigenesis. Genes
Dev. 28:432–437. 2014.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Rech AJ and Vonderheide RH: Dynamic
interplay of oncogenes and T cells induces PD-L1 in the tumor
microenvironment. Cancer Discov. 3:1330–1332. 2013.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Parsa AT, Waldron JS, Panner A, Crane CA,
Parney IF, Barry JJ, Cachola KE, Murray JC, Tihan T, Jensen MC, et
al: Loss of tumor suppressor PTEN function increases B7-H1
expression and immunoresistance in glioma. Nat Med. 13:84–88.
2007.PubMed/NCBI View
Article : Google Scholar
|
|
46
|
Casey SC, Tong L, Li Y, Do R, Walz S,
Fitzgerald KN, Gouw AM, Baylot V, Gütgemann I, Eilers M and Felsher
DW: MYC regulates the antitumor immune response through CD47 and
PD-L1. Science. 352:227–231. 2016.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M,
Nakajima Y, Zhou J, Li BZ, Shi YH, Xiao YS, et al: Overexpression
of PD-L1 significantly associates with tumor aggressiveness and
postoperative recurrence in human hepatocellular carcinoma. Clin
Cancer Res. 15:971–979. 2009.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Zhang P, Ma Y, Lv C, Huang M, Li M, Dong
B, Liu X, An G, Zhang W, Zhang J, et al: Upregulation of programmed
cell death ligand 1 promotes resistance response in non-small-cell
lung cancer patients treated with neo-adjuvant chemotherapy. Cancer
Sci. 107:1563–1571. 2016.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Gupta HB, Deng J, Clark CA, Drerup JM, Wu
B, Sareddy G, Hurez V, Vadlamudi R, Li R and Curiel TJ: Programmed
cell death ligand 1 (PD-L1) regulates tumor initiating cell (TIC)
generation by controlling the stemness gene Oct4 through mTORC1. J
Immunol. 200 (1 Supplement)(167)2018.
|
